BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 27c
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Join SI Premium – FREE
BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.40), $0.27 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $3.26 million.
For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades PulteGroup (PHM) to Outperform
- Wells Fargo Downgrades Canada Goose (GOOS:CN) (GOOS) to Underweight
- Wells Fargo Starts Whirlpool Corporation (WHR) at Equal Weight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
